Skip to main content
. 2015 Apr 16;38(10):695–700. doi: 10.1038/hr.2015.54

Table 3. Adverse events.

Description n (%)
n 72
Any AE, n (%) 64 (88.9)
Any TEAEs, n (%) 56 (77.8)
Any SAEs, n (%) 3 (4.2)
Any drug-related AEs, n (%) 21 (29.2)
Drug-related SAEs, n (%) 1 (1.4)
Discontinuation of study drug because of AEs, n (%) 3 (4.2)
Drug-related TEAEs, n (%) 21 (29.2)
Drug-related TEAEs by MeDRA system organ class, n (%)
 Cardiac disorders 7 (9.7)
 Tachycardia 5 (6.9)
 Acute myocardial infarction 1 (1.4)
 Ventricular extrasystoles 1 (1.4)
 Gastrointestinal disorders 6 (8.3)
 Gingival hypertrophy 3 (4.2)
 Constipation 2 (2.8)
 Diarrhea 1 (1.4)
 General disorders and administration site conditions 3 (4.2)
 Feeling abnormal 1 (1.4)
 Edema 1 (1.4)
 Peripheral edema 1 (1.4)
 Investigations 2 (2.8)
 Elevated gamma-glutamyltransferase 1 (1.4)
 Glucose present in urine 1 (1.4)
 Metabolism and nutrition disorders 2 (2.8)
 Diabetes mellitus 2 (2.8)
 Nervous system disorders 1 (1.4)
 Dizziness 1 (1.4)
 Vascular disorders 2 (2.8)
 Orthostatic hypotension 1 (1.4)
 Flushing 1 (1.4)

Abbreviations: AE, adverse event; MeDRA, Medical Dictionary for Regulatory Activities; SAEs, serious adverse events; TEAEs, treatment-emergent adverse events.